Spread of OXA-23-producing Acinetobacter baumannii ST2 and ST246 in a hospital in Japan.
A total of 1085 strains of Acinetobacter sp. obtained from 280 medical institutions in the Chugoku and Shikoku areas of Japan were investigated between 2011 and 2013. Among these strains, 20 (1.84 %) showing meropenem or imipenem resistance with a MIC of >4 μg ml- 1 were detected. Of these 20 strains, the bla(OXA-23) gene was detected in 17 strains isolated from the same institution. The PFGE patterns of the 17 strains were separated into two clusters, and multi-locus sequence typing showed the sequence types (STs) to be ST2 and ST246. This investigation demonstrated that A. baumannii ST2 of international clone II, which has rarely been isolated in Japan, has not yet spread nationwide.
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Yumi
Y
Kubo
Department of Clinical Laboratory Science, Faculty of Health Care, Tenri Health Care University, Nara, Japan.
Masaru
M
Komatsu
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Emi
E
Tanimoto
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Keiichi
K
Sugimoto
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Satoru
S
Tanaka
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Shiho
S
Migita
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Yoko
Y
Kondo
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Sawa
S
Yano
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Kuniho
K
Maehara
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Ryoko
R
Murata
Department of Clinical Bacteriology, Clinical Laboratory Medicine, Tenri Hospital, Nara, Japan.|Division of Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Akihiro
A
Nakamura
Mitanifujita Hospital, Takamatsu, Japan.
Toshikazu
T
Fujita
FALCO Biosystems, Ltd, Okayama Laboratory Technical Section 2, Okayama, Japan.
Yoichi
Y
Kawata
D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology*; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D006761:Hospitals; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D058885:Multilocus Sequence Typing; D013845:Thienamycins / Q000627:therapeutic use; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics*
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D015378:Imipenem; C466679:beta-lactamase OXA-23; D001618:beta-Lactamases; D000077731:Meropenem